Sign in
AB

AbCellera Biologics Inc. (ABCL)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 revenue of $17.1M vs $7.3M in Q2 2024, driven by $10.4M of licensing revenue; net loss narrowed to $34.7M (−$0.12) from $36.9M (−$0.13) YoY .
  • Results beat S&P Global consensus: revenue $17.1M vs $6.36M estimate (+$10.7M), and EPS −$0.12 vs −$0.16 estimate (beat by $0.04). The revenue beat was largely a one‑off licensing payment linked to the Trianni platform, per CFO commentary (i.e., not recurring) . Values marked with * are from S&P Global.
  • Transition to clinical-stage completed: first participants dosed in ABCL635 Phase 1 (VMS), ABCL575 Phase 1 initiated subsequently; ABCL688 advanced into IND/CTA‑enabling studies .
  • Liquidity remains robust: ~$580M cash and marketable securities plus $173M committed non‑dilutive funding ($753M total liquidity) to fund programs and manufacturing ramp, with runway “well beyond the next three years” .

What Went Well and What Went Wrong

What Went Well

  • Completed transition to clinical-stage biotech; dosing begun in ABCL635 Phase 1 (VMS) and ABCL575 Phase 1 initiated; ABCL688 moved to IND/CTA‑enabling studies .
  • Strong top-line driven by licensing: $17.1M revenue, including $10.4M licensing revenue; management clarified the licensing influx was tied to Trianni and largely non‑recurring .
  • Operating discipline: R&D ($39.2M), S&M ($3.0M), and G&A ($19.0M) all down YoY; loss from operations improved versus a year ago (absence of prior-year impairment) .

What Went Wrong

  • Underlying research fee revenue remains modest and management expects it to trend lower as focus shifts to internal/co‑dev programs, reinforcing dependency on milestone/licensing variability near term .
  • Continued losses as the company invests in clinical and manufacturing capabilities: net loss −$34.7M; H1 operating cash outflow −$44.0M, with ongoing PP&E and CMC/GMP spend .
  • Revenue quality mixed: CFO highlighted the $10M+ licensing component as a one‑off related to Trianni earnout; investors should not extrapolate this cadence .

Financial Results

MetricQ4 2024Q1 2025Q2 2025 (Actual)
Revenue ($USD Millions)$5.1 $4.2 $17.1
Net Loss ($USD Millions)$(34.2) $(45.6) $(34.7)
EPS (Basic & Diluted, $)$(0.12) $(0.15) $(0.12)
Loss from Operations ($USD Millions)—$(62.7) $(49.6)
R&D Expense ($USD Millions)—$42.5 $39.2
S&M Expense ($USD Millions)—$2.8 $3.0
G&A Expense ($USD Millions)—$16.2 $19.0
Liquidity: Cash, Equivalents & Marketable Securities ($USD Millions, period-end)$625.6 (12/31/24) $605.3 (3/31/25) $553.1 (6/30/25)

Revenue mix

Revenue ComponentQ2 2024Q1 2025Q2 2025
Research Fees ($M)$5.453 $4.068 $6.639
Licensing Revenue ($M)$0.370 $0.167 $10.445
Milestone Payments ($M)$1.500 $0.000 $0.000
Total Revenue ($M)$7.323 $4.235 $17.084

Consensus vs actual (Q2 2025)

MetricConsensus*ActualSurprise*
Revenue ($M)$6.36$17.08 +$10.72 / +168.7%*
EPS ($)−$0.16−$0.12 +$0.04*

KPIs

KPI (Cumulative)Jun 30, 2024Mar 31, 2025Jun 30, 2025
Partner-initiated program starts with downstreams93 97 102
Molecules in the clinic14 16 18

Note: Values marked with * are retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY / Q3No formal quantitative guidance providedNo formal quantitative guidance providedMaintained
Operating ExpensesFYNo formal quantitative guidance providedContinued investment in two Phase 1s, preclinical pipeline, and CMC/GMP; cash needs “very manageable”Maintained qualitative framing
Liquidity runwayMulti‑yearStrong liquidity position entering 2025~$580M cash/securities + ~$170M committed funding; runway “well beyond the next three years”Maintained/affirmed
Manufacturing (CMC/GMP)2025Facility coming online in 2025 (prior)“On track to come online at the end of 2025”Reiterated timeline
Clinical milestones — ABCL6352025–2026Start Phase 1 in 2H25 (prior)Dosing begun; initial safety/efficacy readout mid‑2026Updated (execution underway)
Clinical milestones — ABCL5752025–2026Start Phase 1 in 2H25 (prior, May NOL) Phase 1 ongoing; first participants dosed Aug 27, 2025; data mid‑2026Updated (execution underway)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024, Q1 2025)Current Period (Q2 2025)Trend
Transition to clinical stageTargeting Phase 1 starts for ABCL635 & ABCL575 in 2025 Clinical-stage achieved; ABCL635 dosing begun; ABCL575 Phase 1 initiated Positive execution
Revenue mix (research vs licensing)Low/mid single-digit revenues; research fees focus $10.4M licensing one‑off from Trianni; research fees expected to trend lower as focus shifts internal/co‑dev Mixed; licensing volatile
Liquidity & runway>$800M available liquidity entering 2025 ~$750M total availability; runway well beyond 3 years Stable/adequate
Manufacturing/CMCBuilding integrated clinical manufacturing capabilities Facility on track to come online end 2025; ongoing PP&E investments On track
Regulatory/clinical risk for NK3R class—Focus on efficacy (target engagement) and safety; antibody design expected to mitigate small-molecule class issues (somnolence, liver tox) Addressed proactively

Management Commentary

  • “This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company.” — Carl Hansen, CEO, on initiating dosing in ABCL635 Phase 1 .
  • “We have around $750 million in total available liquidity to execute on our strategy… we have sufficient liquidity to fund well beyond the next three years of increasing pipeline investments.” — Andrew Booth, CFO .
  • On revenue quality: “This was definitely a one-off payment related to activities post the acquisition of Trianni… not something that we would expect to have happen in the future.” — CFO on Q2 licensing revenue .
  • On ABCL575: “Our modeling predicts that a 300 mg dosing… every six months should achieve circulating concentrations above the efficacy threshold observed for amlitelimab,” pending clinical confirmation .

Q&A Highlights

  • Licensing revenue cadence: Q2’s ~$10M+ licensing was a non‑recurring earnout-related item; not indicative of run-rate .
  • ABCL635 Phase 1 design and key risks: SAD/MAD with biomarkers (LH/FSH, sex hormones), POC up to ~80 women; main scientific risk is sufficient target engagement; initial safety/efficacy data mid‑2026 .
  • NK3R class safety: Antibody specificity (NK3R only) and metabolism profile expected to mitigate class somnolence/liver tox seen with small molecules; to be demonstrated in trial .
  • ABCL575 program path: Phase 1 in Canada now underway; engaging FDA to lay groundwork for Phase 2 (likely including U.S. sites) .
  • Revenue mix outlook: Research fees likely trend lower as internal/co‑dev emphasis grows .

Estimates Context

  • Q2 2025 results vs S&P Global consensus: revenue $17.08M vs $6.36M estimate (beat by $10.72M), EPS −$0.12 vs −$0.16 estimate (beat by $0.04). Given CFO’s clarification that the licensing revenue was a one‑off, forward revenue estimates may need to normalize underlying research/licensing cadence and incorporate milestone timing, rather than extrapolating Q2’s magnitude . Values marked with * are from S&P Global.
  • Actuals anchored to company filings: revenue $17.084M; EPS −$0.12 .

Key Takeaways for Investors

  • Quality of beat matters: The sizable revenue beat was largely a non‑recurring licensing item; do not extrapolate Q2 top-line into H2 without corresponding visibility on licensing/milestones .
  • Clinical inflection 2025–2026: With ABCL635 dosing underway and ABCL575 Phase 1 initiated, mid‑2026 readouts are the next major catalysts; execution and early biomarker signals will shape valuation .
  • Liquidity buffers risk: ~$753M in total availability provides multi‑year runway through Phase 1s, preclinical expansion, and CMC/GMP completion (end‑2025), limiting near‑term financing risk .
  • Revenue mix shifting: Expect lower research fees as internal pipeline investment steps up; near‑term P&L may remain loss‑making absent milestones .
  • Watch external read‑throughs: Outcomes from the NK3R and OX40L classes (competitor data/approvals) can materially influence perceived probability of success for ABCL635/ABCL575 .
  • Operating discipline: YoY OpEx reductions (and lack of 2024 impairment) improved operating loss; monitor OpEx trajectory as manufacturing comes online .
  • Near-term catalysts: ABCL575 Phase 1 dosing (initiated Aug 27), ongoing ABCL635 Phase 1 enrollment/biomarkers, manufacturing facility milestones, and any partner-driven molecules entering clinic .

Footnote: Consensus estimates and surprise metrics marked with * are values retrieved from S&P Global.